
Metabolon Launches Metabolite Biomarker Panels for Liver and Kidney Function
Metabolon, a contract research organization focused on metabolomic research in life science research, diagnostics, and therapeutic development has unveiled its new Liver Fibrosis and Kidney Function Discovery Panels. These panels are designed to allow researchers to have a wholistic view of metabolic biomarkers associated with the respective diseases.
Chronic liver disease claims the lives of two million people annually worldwide, and nearly 36 million adults in the United States suffer from chronic kidney disease. A vast majority of these patients are unaware of their condition due to the lack of early detection mechanisms. New drugs such as Novo Nordisk’s Ozempic could also provide treatment alternatives for patients with kidney disease.
Metabolon’s Liver Fibrosis and Kidney Function Discovery Panels are part of the Metabolon Discover portfolio, providing metabolomics services that enable researchers to study various metabolites within the complex biological pathways linked to these health issues. These advanced panels incorporate visualization tools that facilitate data comparison across diverse datasets, helping researchers identify and comprehend statistically significant alterations in metabolite abundance.
The Liver Fibrosis Discovery Panel comprises 105 metabolites associated with multiple biological processes relevant to liver fibrosis. Researchers can now confidently identify markers related to liver fibrosis, gaining essential insights into mechanistic processes, personalized medicine, and drug development. In parallel, the Kidney Function Discovery Panel evaluates 84 metabolites linked to biochemical processes that affect kidney function. Through metabolomic profiling, researchers have identified several metabolites associated with changes in carbohydrate, amino acid, nucleotide, and lipid metabolism, rendering metabolic profiling an important tool for advancing kidney disease research.
More companies have been developing early detection tests for both liver and kidney disease such as Fibronostics who recently announced a partnership with Stone Health to commercialize its LIVERFASt™ test and Renalytix who recently received FDA approval and Medicare reimbursement for its KidneyIntelX test.